A recent preprint study has shed light on why adverse events have been observed following a COVID-19 messenger RNA (mRNA) vaccination.
The study, led by researchers from Thomas Jefferson University, found that the lipid nanoparticles (LNPs) used to transport mRNA in COVID-19 vaccines could “inhibit” and “alter” immune responses in mice.
LNPs are shells of lipids that envelope mRNA to prevent degradation and detection by our body’s immune system.
LNPs are not mRNA, simply an envelope to transport the mRNA cargo.
Both the Pfizer and Moderna mRNA COVID-19 vaccines use LNPs to deliver mRNA spike protein sequences into human cells. Once human cells received the mRNA sequences, the cells will then manufacture spike proteins, triggering an immune response.
It was originally intended that the LNPs discreetly deliver mRNA sequences into the cells to produce spike proteins, and in doing so, form immunity against the COVID-19 virus.
However, many studies in mice have since found that the LNPs, claimed to be non-toxic and safe, are actually highly inflammatory.
These nanoparticles are highly durable and can last for 20 to 30 days in the body. While they persist in the body, it is likely they will continue to activate the immune system, leading to immune exhaustion and non-responsiveness.
The Thomas Jefferson study also shared similar findings. The researchers investigated how LNPs affect the immune system by injecting mice with the same LNPs used in Pfizer’s vaccines, and some mice were even double-dosed.
Inflammation and immune responses in mice are not sure signs that the same will happen in humans. Nonetheless, mice have long been used to test for safety and efficacy in drugs for human use; signs of immune problems are an indication of possible health risks in humans.